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A B S T R A C T   
Perfluorocarbons hold great promise both as imaging agents, particularly for 19F MRI, and in therapy, such as 
oxygen delivery. 19F MRI is unique in its ability to unambiguously track and quantify a tracer while maintaining 
anatomic context, and without the use of ionizing radiation. This is particularly well-suited for inflammation 
imaging and quantitative cell tracking. However, perfluorocarbons, which are best suited for imaging – like 
perfluoro-15-crown-5 ether (PFCE) - tend to have extremely long biological retention. Here, we showed that the 
use of a multi-core PLGA nanoparticle entrapping PFCE allows for a 15-fold reduction of half-life in vivo 
compared to what is reported in literature. This unexpected rapid decrease in 19F signal was observed in liver, 
spleen and within the infarcted region after myocardial infarction and was confirmed by whole body NMR 
spectroscopy. We demonstrate that the fast clearance is due to disassembly of the ~200 nm nanoparticle into 
~30 nm domains that remain soluble and are cleared quickly. We show here that the nanoparticle ultrastructure 
has a direct impact on in vivo clearance of its cargo i.e. allowing fast release of PFCE, and therefore also bringing 
the possibility of multifunctional nanoparticle-based imaging to translational imaging, therapy and diagnostics.   
1. Introduction 
In the recent decade, there has been much renewed interest in liquid 
perfluorocarbons (PFCs) as contrast agents for fluorine-19 Magnetic 
Resonance Imaging (19F MRI) [1–3], particularly for cell tracking ap-
plications. 19F MRI is of particular interest due to the possibility of 
combining background-free in vivo imaging with the precise anatomic 
localization capability of conventional 1H MRI but without the use of 
ionizing radiation. Moreover, the 19F signal can be quantified directly 
from the image [4]; unlike conventional contrast agents, such as gado-
linium (Gd) and super paramagnetic iron oxide (SPIO), which alter the 
existing proton signal [5,6]. Such unique properties of 19F MRI have 
enabled quantitative cell tracking for immunotherapy [7–11], and 
inflammation imaging applied to prevalent diseases such as myocardial 
infarction, multiple sclerosis and rheumatoid arthritis among many 
others [12–17]. Despite the unique opportunities that 19F MRI offers, the 
technique is hampered by sensitivity issues. Liquid PFCs with high 
fluorine density can satisfy the requirements for improved 19F MRI 
detection sensitivity. Specifically for imaging applications, single reso-
nance PFCs are the most attractive contrast agents as all fluorine atoms 
contribute to the signal and chemical shift artefacts are avoided [18]. 
However, these PFCs also have the longest in vivo half-lives, of up to 250 
days [19]. 
Liquid PFCs are both hydrophobic and lipophobic and therefore need 
to be stabilized to achieve dispersibility in aqueous media as a prereq-
uisite for their use in biological systems [20,21]. Commonly, PFC-based 
imaging agents are formulated as core-shell or single-core nano-
emulsions (NEs) through emulsification with a lipid surfactant [12,22] 
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or as single-core nanocapsules (NCs) using a biodegradable polymer as 
the stabilizing agent [23,24]. For instance, van Heeswijk et al. reported 
in vivo imaging of atherosclerotic plaques using a PFC nanoemulsion, 
and Foster and colleague used the commercially available CelSense to 
image macrophage infiltration into tumors [25,26]. However, a major 
issue with the use of PFCs is their long biological half-life. In particular, 
PFCs suitable for imaging, such as perfluoro-15-crown-5-ether (PFCE) 
and the linear perfluoropolyether (PFPE), have biological half-lives well 
over 100 days and show slow local clearance [27,28]. This results in two 
issues; the first being safety concerns associated with slow clearance, 
and the second being local retention, which make long-term spatio-
temporal follow-up challenging. For instance, although PFC emulsions 
have been reported as safe for human use, clinical information on this 
topic is sparse and involves only short follow-up periods [29–31]. 
Therefore, the long biological retention times of PFCs may complicate 
regulatory approval of PFC-containing imaging agents, analogous to the 
recent concerns with gadolinium deposition [32]. In addition, the poor 
local mobility of PFCs results in their retention at the site of their initial 
accumulation. For instance, PFCE-NEs used for inflammation imaging 
have been shown to remain at the location of inflammation long after 
the inflammation has subsided [28]. A similar phenomenon was 
observed when tracking ex vivo-labelled cells, where the PFC label 
remained at the administration site long after the labelled cells have 
died [33,34]. Therefore, long-term follow-up and assessment of tem-
poral dynamics can be a problem with long-lingering imaging agents, 
therefore there is a need for PFC imaging agents with faster in vivo 
clearance. 
Polymeric carriers can provide a versatile platform for the design of 
imaging agents [35]. Poly (lactic-co-glycolic acid) (PLGA) is among the 
most commonly studied materials as carriers due to its biocompatibility, 
tunable degradation profile and long clinical history for various appli-
cations [36–40]. We previously reported the encapsulation of PFCE in 
PLGA nanoparticles (NPs), and demonstrated their applications in 
multi-modal imaging of therapeutic cells [41–46]. A detailed structural 
characterization of these NPs revealed the presence of multiple, distinct 
PFCE domains stabilized by the polymeric matrix as a multi-core NP 
[47]. In the present study, we investigate additional advantageous 
properties of these imaging agents in comparison to single-core alter-
natives formulated as NEs and NCs in terms of their in vivo clearance. 
The biological half-lives of all three formulations (NE, NC, NP) were 
quantitatively determined using 19F MRI and were found to differ 
significantly depending on the formulations’ ultrastructure. In vitro 
degradation analyses performed with atomic force microscopy and dy-
namic light scattering, as well as cell experiments supported our hy-
pothesis that in vivo clearance rate strongly depends on the 
ultrastructure of the formulations. We further show the faster clearance 
of the multi-core NPs in a myocardial infarction model as a clinically 
applicable representative of inflammation imaging. Overall, our find-
ings present the direct link between NP ultrastructure and their in vivo 
clearance rate. The multi-core NP can potentially satisfy the re-
quirements of fast-clearing, highly sensitive 19F MRI agents suitable for 
clinical imaging and diagnostics. 
2. Methods 
2.1. Materials 
Perfluoro-15-crown-5-ether (PFCE) (Exfluor, TX, USA for the NPs 
and NCs or Fluorochem Ltd., Hadfield, GB for the NEs), poly (D,L-lac-
tide-co-glycolide) (PLGA) resomer RG 502H, lactide:glycolide molar 
ratio 50:50 (Evonik, Germany), dichloromethane (Merck, Germany), 
poly (vinyl alcohol) (PVA, 80% hydrolized) (Sigma-Aldrich, MO, USA), 
indocyanine green (Akorn inc., IL, USA), Carboxy Atto647 N (Atto-tec, 
Germany), Phosphate buffered saline (PBS) (Braun, Germany), 
Dichloromethane (DCM) (VWR, the Netherlands), Poly (propylene 
oxide) (PPO) (Sigma Aldrich, MO, USA). Phosphate buffer, Glycerol 
both from Carl Roth GmBH und Co. KG, Karlsruhe, Germany. 
2.2. Synthesis of multicore nanoparticles 
The synthesis is previously described [44]. In short, a triphase min-
iemulsion synthesis technique was used; structure formula of the main 
components is shown in Fig. S9. Organic phase consisted of 100 mg of 
PLGA and 0.5 mg of indocyanine green or 0.05 mg of Atto647 dissolved 
in 3 mL of dichloromethane with the addition of PPO, fluorous phase 
consisted of 900 μL PFCE, aqueous phase consisted of 1.96% (wt/wt) 
PVA surfactant in ultrapure water. The organic phase and fluoruos phase 
were premixed by agitation in a Pasteur’s pipet and was immediately 
added to 25 mL of the aqueous phase and emulsified for 3 min with the 
use of a Branson S250 probe sonicator (Branson Sonic Power, CT, USA) 
at 40% amplitude. The solvent was evaporated overnight at 4 C. Next, 
the particles were collected by centrifugation, washed 4 times with 
deionized water, and then freeze-dried. 
2.3. Synthesis of core-shell nanoemulsions 
PFC particles are produced as described elsewhere; structure formula 
of the main components is shown in Fig. S9 [48]. In brief, 0.24% (bNE) 
or 2.4% (sNE) (w/w) phospholipid (Lipoid E80S, Lipoid GmbH, Lud-
wigshafen, Germany) is dissolved in 10 mM phosphate buffer (7 mM 
Na2HPO4, 3 mM NaH2PO4, pH 7.4 isotonized with 2.5% (w/w) Gylcerol) 
and pre-emulsified for 30 min on a stirrer (IKA-Werke GmbH & Co. KG, 
Staufen, Germany). Afterwards, 10% (w/w) perfluoro-15-crown-5 ether 
and 0.0025 mol% Cy5-labelled phosphatidlyethanolamine (Avanti Polar 
Lipids Inc., Alabaster, USA), are added, again followed by a 30 min 
period of stirring in the dark. Thereafter, a crude emulsion is formed by 
high shear mixing (Ultra Turrax TP 18/10, IKA-Werke GmbH & Co. KG, 
Staufen, Germany). The final emulsion is produced by high shear ho-
mogenization over 10 cycles at 1000 bar, using an M   110P Micro-
fluidizer (Microfluidics International Corporation, Westerwood, USA). 
PFCs are heat-sterilized in glass vials (VWR, Radnor, USA) under stan-
dard conditions (121 C, 1 bar, 22 min; HMC Europe GmbH, Tüßling, 
Germany). 
2.4. Synthesis of core-shell nanocapsules 
Nanocapsules were synthesized using an adapted NP synthesis pro-
tocol. An identical primary emulsion, consisting of PLGA, DCM and 
PFCE was added to the aqueous phase, however with sodium cholate 
(25 g, 1.5 % wt/wt) as surfactant. This mixture was sonicated as before. 
Overnight the solvent was evaporated. Subsequently, the surfactant was 
exchanged to PVA (10 g of 1.96 % wt/wt) by stirring at 4 C for 5 d. After 
washing, the NCs were freeze-dried. 
2.5. Imaging agent characterization 
Hydrodynamic radius was measured with DLS experiments per-
formed on a Malvern Zetasizer ZS Nano (Malvern, United Kingdom). 
Samples were measured at a concentration of 0.01 mg/mL in a dispos-
able cuvette. 
PFCE content of NPs and NEs was measured with NMR experiments 
performed on a 9.4 T Bruker Avance III 400 MHz instrument, equipped 
with a BBFO-probe. NPs or NCs were dissolved in D2O (Sigma Aldrich, 
Germany) and a 1% TFA (Trifluoracetic acid) (Sigma Aldrich, Germany) 
internal reference was added. The mixture was measured at   85 ppm 
with a sweep with of 40 ppm and 8 averages with an interscan delay of 
25 s. Data was analyzed with Mestrenova 10.0.2. 
Particles were analyzed on a ζ-Sizer (Microtrac GmbH, Krefeld, 
Germany), run with Microtrac FLEX 10.5.0 Software (Microtrac GmbH, 
Krefeld, Germany). For this purpose, 20 μl of the respective substance 
were mixed with 1 mL ddH2O. A measurement protocol was used which 
consisted of 10 cycles, 90 s each. 
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2.6. In vivo biodistribution and clearance experiments 
8-14-week-old wild type C57Bl/6 male and female mice were pur-
chased from Charles River Laboratory, Germany and maintained under 
specific pathogen-free conditions, received ad libitum standard mouse 
chow diet and tap water, in the Central Animal Laboratory in Nijmegen, 
the Netherlands and the Zentrale Einrichtung für Tierforschung und 
wissenschaftliche Tierschutzaufgaben (ZETT) in Düsseldorf, Germany. 
All animal experiments in Nijmegen were conducted in accordance to 
the guidelines for animal care of the Nijmegen Animal Experiments 
committee under Central Committee of Animal experiments permit 
(AVD1030020173444). All animal experiments in Düsseldorf were 
conducted in accordance to the EU Directive 2010/63/EU on the pro-
tection of animals used for scientific purposes (Landesamt für Natur, 
Umwelt und Verbraucherschutz (LANUV) Nordrhein – Westfalen, 
Recklinghausen, Germany; AZ 81–02.04.2018. A007). 
At the start of the NP and 90 nm and 200 nm NE clearance experi-
ments, 56 mice were injected in the tail vein with 20 mg of NPs dissolved 
by sonication in 0.9% NaCl or a fluorine equivalent amount of NEs. Per 
nanoparticle, 5 mice were imaged on day 1 after injection and subse-
quently sacrificed, 6 mice were imaged at timepoints 1, 3, 6 and 24 h, 6 
mice were imaged at timepoints 4, 7, 14, 21 and 28 days and additional 
5 mice were imaged at timepoints 2 h and 2, 4, 7 and 14 days, after 
which they were sacrificed. 
To assess NC clearance, 5 mice were injected in the tail vein with 20 
mg of NCs dissolved by vortexing in 0.9% NaCl. Mice were imaged 2 h 
and 2, 4, 7 and 14 days after injection, after which they were sacrificed. 
Liver and spleen of NP, NE and NC injected mice were collected for 
histology. 
For the toxicity experiments mice received nanoparticles at a con-
centration of 100 mg/mL. Via intravenous tail vein injection three mice 
received 400 μl, three mice received a total of 600 μl in two   1 h spaced- 
injections and 3 control mice were not injected. Nanoparticle concen-
tration were chosen as the highest concentration without significant 
increase of viscosity, injection volumes are highest volumes that do not 
cause volume overload. Two weeks after injection the liver and spleen 
were removed, fixed in 10% of formalin and snap frozen. Five μm cry-
osections were cut and stained with routine hematoxylin and eosin 
(H&E). 
During imaging, mice were anesthetized using isoflurance, 3% in-
duction and 1.5–2% maintenance, to achieve a stable breathing rate of 
60–90/minute. Core temperature was kept between 36 and 37.5 C 
using an in-house build water heated matrass in Nijmegen and by 
heating the cooling system of the MRT to 32 C in Düsseldorf. A refer-
ence tube, containing a homogeneous solution of the injected imaging 
agent diluted 1:10 in 0.9% NaCl, was placed next to the animal to allow 
for quantification. 
2.7. Magnetic resonance imaging 
Image data was recorded on a Bruker BioSpec 117/16 11.7 T MRI 
(Bruker, Germany) in Nijmegen and a Bruker AVANCE III 9.4 T wide- 
bore nuclear MR spectrometer (Bruker, Germany) in Düsseldorf, using a 
dual-tuned birdcage coil. 
2.8. Phantom experiments 
NPs where dissolved in phosphate buffered saline at concentrations 
of 5, 10, 15, 20, 25, 30, 40 and 50 mg/mL and sonicated thoroughly to 
produce a homogeneous solution and transferred to PCR tubes. A 3D 
RARE sequence with parameters: TR 1500 ms, TE 6.62 ms, turbo factor 
44, 2 averages, matrix 64  44  16, field of view of 32  22  32 mm3, 
imaging time 48 s was used to image the phantom tubes. T1 and T2 
mapping was used to determine T1 and T2 of various concentrations of 
NPs. T1 mapping was done using an inversion recovery sequence with a 
RARE readout. Parameters: 8 inversion recovery images between 300 ms 
and 1400 ms, constant TR 1800 ms, TE 4.32 ms turbo factor 35, 20 
averages, field of view 35  35  3 mm3, voxel size 1  1  3 mm, scan 
time 4:48 min. T2 mapping was done using a 2D RARE with 8 echo 
images between 50 ms and 750 ms. TR 1500 ms, TE 50–750 ms, turbo 
factor 2, 20 averages, field of view 35  35  3 mm3, voxel size 1  1 
3 mm3, scan time 8:30 min. 
2.9. In vivo mouse experiments 
For 19F imaging in Nijmegen a 3D RARE sequence was used, imaging 
parameter: TR 1500 ms, TE 6.62 ms, turbo factor 44, 32 averages, matrix 
64  44  16, field of view of 32  22  32 mm3, imaging time 12:48 
min. Excitation frequency 470.743 MHz and an excitation bandwidth of 
1 kHz to avoid isoflurane artefacts. Co-registration of 1H anatomical 
images was done with a respiratory triggered unspoiled 2D FLASH, 
imaging parameters: TE 6 ms, TR 350 ms, FA 80 deg, 2 averages, matrix 
256  256, field of view 32  32 mm, 24 1 mm thick slices for an im-
aging time ~10 min depending on the respiratory rate. 
For 19F imaging in Düsseldorf a RARE-sequence was used, imaging 
parameters: TR 2500 ms, TE 69.88 ms, 128 averages, matrix 64  64, 
field of view 2.56  2.56 cm2, 2 mm thick slices, 13 slices, imaging time 
10:40 min, excitation frequency 376.46 MHz. Co-registration of 1H 
anatomical images was done with a RARE-sequence, imaging parame-
ters: TE 36.23 ms, TR 2500 ms, 13 averages, matrix 256  192, field of 
view 2.56  2.56 cm2, 2 mm thick slices, 13 slices, imaging time 2:30 
min, excitation frequency 400.13 MHz. For data analysis, matrices were 
reconstructed to 256  256. 
To investigate bladder and gallbladder PFCE content, an adapted 19F 
sequence with higher detection threshold was used; single slice 2D 
RARE, in plane resolution 1  1 mm, 6 mm slice to cover the entire 
bladder, turbo factor 32, 500 averages. 
2.10. Data analysis of in vivo 19F MRI measurements 
19F signal intensity of the entire liver and spleen was determined in 
vivo to allow for longitudinal follow-up of the imaging probe. Follow-up 
of individual animals decreased data variance otherwise induced by 
individual anatomical differences or exact injection volume. When 
reporting the longitudinal follow-up of the probes, the 19F signal for 
each individual animal at timepoint 3 h was set as 100% and all other 
time-points were reported relative to 3 h signal. 
Offline data analysis in Düsseldorf was performed using Fiji using the 
Bruker plugin. Regions of interest (ROIs) where drawn over the liver, 
spleen and a background region in one corner of the image of all slices 
containing the liver or spleen. For the liver and spleen, signal-to-noise 
ratio (SNR), in arbitrary units, was calculated (sum of (mean 19F- 
Signal of the ROI in the respective slice – mean 19F-signal of the back-
ground ROI)/means standard deviation of the background ROI). Data 
analysis in Nijmegen was performed using OsiriX viewer (Pixmeo SARL, 
Switzerland). Regions of interest where drawn over the liver, spleen, 
background region in one corner of the image and reference tube, and 
reconstructed into volumes of interest. The liver and spleen signal were 
corrected to the reference tube and the background signal was 
subtracted. 
Imaging agent biodistribution was measured using in vivo 19F MRI of 
animals injected with 20 mg of NP or NC or a fluorine-equivalent 
amount of NE or sNE. 19F-containing organs were segmented into vol-
umes of interest, these organs were liver, spleen, bone marrow and intra- 
abdominal lymph nodes. From this organ-specific signal, noise was 
subtracted and the signal was normalized to an internal reference tube. 
2.11. Ex vivo 19F MRI of the liver 
NPs or bNEs were injected intravenously and after 28 days, the liver 
was excised, washed in PBS and subsequently fixed in 4% para-
formaldehyde overnight. To avoid tissue destruction due to excessive 
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fixation, organs were then washed again in PBS and stored in PBS at 4 C 
and under light protection. 
First anatomical 1H images were obtained using a RARE-sequence 
with the following imaging parameters: TR 2500 ms, RARE factor 16, 
one average, matrix 256  192, field of view 2.56  2.56 cm, 2 mm slice 
thickness, 13 slices, imaging time 0.5 min. Subsequently, 19F MRI was 
conducted from the same field of view using a standard 19F RARE 
sequence. Imaging parameters: TR 2500 ms, RARE factor 32, 128 av-
erages, matrix 64  64, field of view 2.56  2.56 cm, 2 mm slice 
thickness, 13 slices, imaging time ~11 min. Data analysis was performed 
with Fiji [49] using the MRI File Manager (Bruker) plugin [50]. Regions 
of interest (ROIs) where drawn to enclose the liver and a background 
region was placed outside the liver in the corner of the images. The 
signal-to-noise ratio (SNR) of the 19F signal was calculated: (Mean 
19F-signal of the liver – mean 19F-signal of the background (BKG))/Mean 
standard deviation (SD) of the background ROI). 
2.12. Nanoparticle degradation 
Nanoparticles where dissolved in PBS (pH 7.4) or 2 M NaOH (pH 14) 
at a concentration of 10 mg/mL and kept on agitation at 750 rpm at 
37 C for 2 weeks. On day 0, 3, 7 and 13 nanoparticle size was analyzed 
using dynamic light scattering (DLS) on a Nanotrac Flex In-situ Analyser 
(Microtrac, Germany). On day 0, 1 week and 2 weeks after incubation 
nanoparticle size was imaged using atomic force microscopy (AFM). 
Atomic force microscopy (AFM) images of nanoparticles were ob-
tained with a Catalyst BioScope (Bruker) coupled to a confocal micro-
scope (TCS SP5II, Leica). 100 μL of 10 mg/mL particle suspension was 
dried on clean glass substrates and particles were imaged in peak-force 
tapping mode using a silicon nitride cantilever with nominal spring 
constant of 0.4 N/m (Bruker). AFM images were analyzed using Nano-
Scope analysis software (Bruker). 
2.13. Cellular uptake and viability 
Cultured cell lines (CHO - ECACC 85050302-, RAW264.7 - ECACC 
91062702-, J774.2 - ECACC 85011428 - and THP-1 – ECACC 88081201) 
and primary cells (murine blood immune cells, cells isolated from mu-
rine livers and spleens) were incubated ex vivo with 2.5 μl NEs and NCs 
and 5 μl of NPs over a period of 40 (blood immune cells) or 80 min. For 
1H/19F-MRI measurements CHO and RAW264.7 cells were incubated for 
2 and 24 h. Cultured cells were cultivated under standard conditions 
(37 C, 5% CO2) in complete medium (DMEM high glucose (Merck 
KGaA, Darmstadt, Germany) with 10% heat-inactivated FCS (Biochrom, 
Berlin, Germany), 1% HEPES (Thermo Fisher Scientific Inc., Waltham, 
USA), 1% Sodium-Pyruvate (Thermo Fisher Scientific Inc., Waltham, 
USA) and 1% Penicillin/Streptomycin (Thermo Fisher Scientific Inc., 
Waltham, USA). 
Primary cells were obtained from male C57Bl/6 mice at an age of 
10–14 weeks. Blood was collected from the tip of the tail of living ani-
mals. Organs were digested by collagenase II (6 mg Collagenase II – 
SERVA Electrophoresis GmbH, Heidelberg, Germany - and 20 μl DNAse 
(Merck, Taufkirchen, Germany) in 4,98 mL PBS; 15 min at 37 C on a 
shaker) and dissociated into single cells by passing them through a 40 
μm cell strainer. Dissociation was followed by lysis of erythrocytes using 
in-house prepared lysis buffer (up to 5 times, 10 min on ice each) and an 
FcR blocking step with 1:20 FcR Blocking reagent (Miltenyi Biotec, 
Bergisch Gladbach, Germany) for 10 min on ice. This was followed by 
particle incubation at 37 C (blood: additional incubation at 4 C) on a 
shaker with sequential withdrawal of samples at 0, 5, 10, 20, 40 and 80 
min. 
For flow cytometry, cells were stained with the following antibodies: 
Blood immune cells/Spleen cells: CD45-PerCP rat anti mouse, 30-F11 
(BD, Heidelberg, Germany), 1:100; CD11b-APC/Fire 750 rat anti 
mouse/human, M1/70 (BioLegend, San Diego, USA), 1:1000; CD3-PE/ 
Cy7 Armenian hamster anti mouse, 145-2C11 (Biolegend, San Diego, 
USA), 1:200; CD19-PE rat anti mouse, 1D3 (BD, Heidelberg, Germany), 
1: 400. Liver cells: CD45-PE/Cy7 rat anti mouse, 30-F11 (BD, Heidel-
berg, Germany), 1:400; CD11b-APC/Fire 750 rat anti mouse/human, 
M1/70 (BioLegend, San Diego, USA), 1:1000; F4/80-PE rat anti mouse, 
BM8 (BioLegend, San Diego, USA), 1:100; CD31-PerCP Cy5.5 rat anti 
mouse, 390 (BioLegend, San Diego, USA), 1:200. For live-dead staining, 
1 μg/mL DAPI was used. For washing of the cells and ultimate mea-
surements MACS-buffer (PBS with 0,5% BSA Fraktion V and 5 mM 
EDTA, pH 7,4) was used. Flow cytometry was performed on a FACS 
CantoII, run with FACSDiva software (BD Bioscience, Heidelberg, Ger-
many), offline data analysis was performed using FlowJo software 
(FlowJo, LLC, Ashland, USA). To calculate the number of positive cells, 
the amount of Cy5/Atto647 positive cells was determined. Mortality 
was determined by analyzing the percentage of living cells (DAPI 
negative) normalized to the 0 min sample, then compared to an un-
treated controls. 
For 1H/19F MRI, cells were fixed in 4% PFA (Labochem international, 
Heidelberg, Germany) for 10 min on ice, followed by pelleting. For 
quantification of the 19F-signal in the pellets, a transverse section of the 
pellets was performed, using a RARE-sequence, imaging parameters: TR 
2500 ms, TE 52.49 ms, 1024 averages, matrix 32  32, field of view 
2.56  2.56 cm2, 1 mm thick slices, 12 slices, imaging time 42:40min, 
excitation frequency 376.46 MHz. The SNR of the pellets was calculated 
and different substances were compared. 
2.14. Ischemia reperfusion myocardial infarction model 
Wild type C57Bl/6 J mice (n  6), 8-12-week-old, were anaes-
thetized with an intraperitoneal cocktail of medetomidine, midazolam 
and fentanyl. Animals were intubated and mechanically ventilated. The 
left anterior descending coronary artery is approached via a left thora-
cotomy between the 3rd and 4th rib. The coronary artery was ligated for 
45 min using a suture and a piece of plastic tubing, approximately 1 mm 
under the left atrium. When anesthetic depth became insufficient, 0.5% 
isofluorane was started. The ligature was removed and the thorax was 
closed after the 45 min of ischemia. The animals were injected with 400 
μl of NPs dissolved at 100 mg/mL in PBS 3 h after waking up. 
2.15. Feces NMR 
Mouse feces produced between 0 and 24, 24–48 and 48–72 h after 
injection were collected to be investigated for PFCE content. Feces were 
dissolved in PBS and imaged using a 2D RARE sequence (in plane res-
olution 1  1 mm, 4 mm thick slices, TF 32, 512 averages). Dissolving 
the mouse feces in PBS did not result in a homogeneous solution, 
therefore MRI results might be non-representative due to line broad-
ening or T2 shortening. A homogeneous feces samples was prepared by 
putting the feces in liquid nitrogen and crushed in a mortar until a fine 
powder was formed. The powder was subsequently dissolved in 500 μl of 
D2O by excessive sonication. An 1% TFA internal reference was added to 
this homogeneous feces solution and NMR was performed (8 averages 
with a 25 s interscan delay). 
2.16. Statistics 
For statistical analysis of the cell labeling and viability experiments, 
means and SD of individual experiments were calculated, followed by 
two-way ANOVA with Bonferroni post hoc analysis. Statistical analysis 
of the in vivo imaging data was done using Graphpad Prism 7 (GraphPad 
Software, San Diego, CA, USA). Decrease in organ signal was fitted with 
a 2-phase decay function. Significance of this differences was calculated 
with a linear regression analysis of the decrease in signal. Statistical 
significance of the differences between organ signal at specific time 
points between NPs and NEs was calculated with the Holm-Sidak 
method. A p-value of <0.05 was considered significant. 
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2.17. Data availability 
The data that support the findings of this study are available from the 
corresponding author upon reasonable request. 
3. Results 
3.1. Characterization of imaging agents used 
Two distinct PFCE-containing imaging agents were compared 
initially: core-shell or single-core lipid-based NEs and multi-core PLGA- 
based NPs (Fig. 1a). Dynamic light scattering (DLS) and atomic force 
microscopy (AFM) show that the NPs and NEs have a hydrodynamic 
diameter of 191 nm and 178 nm respectively, and a monodisperse size 
distribution (Fig. 1b and c). The lipid based NEs have a slightly more 
negative ζ-potential compared to the PLGA-based NPs (Table S1). MRI of 
NP-containing phantoms shows a highly linear (R2 > 0.99) relationship 
between NP concentration and signal intensity, suitable for quantifica-
tion of NP concentrations (Fig. S1). Additionally, a single resonance 
peak and a favorable T2/T1 relaxation time ratio indicate that these 
PFCE containing NPs have optimal characteristics for imaging (Fig. S1). 
3.2. Only multicore NPs show significant in vivo clearance 
We applied repeated 1H/19F MRI measurements to assess the bio-
logical half-life of NPs and NEs after intravenous injection in mice. A 
total of 32 mice divided over two academic centers were injected with 
20 mg of NPs or a fluorine-equivalent amount of NEs. The animals were 
imaged at multiple timepoints early after injection (1 h, 3 h, 6 h or 24 h) 
to assess the kinetics in the liver and spleen, which are well known sites 
of PFC deposition [28]. In addition, we followed the 19F signal in the 
liver and spleen over the course of five weeks to study the biological 
half-life of the PFCE derived 19F signal. To this end, we used combined 
1H/19F MRI to determine the signal in the blood and also in the liver and 
spleen. Figs. 1d and S2 shows representative sections of the liver and 
spleen for the NPs and NEs at various timepoints after injection. These 
images show that we observed strong 19F signals in the liver after 3 h for 
both NPs (upper row) and NEs (lower). However, whereas the 19F signal 
in the liver remained quite stable over time after injection of NE, the 19F 
signal of the NPs showed a decrease even after day 1 which then further 
progressively declines over time. Quantification of the 19F signal in the 
liver is shown in Fig. 1e where the 19F MRI organ signal intensity was 
expressed as a percentage of the highest signal (3 h post injection). The 
NPs showed a significantly decreasing slope (p  0.0001), the NEs did 
not (p  0.77). After four weeks, 66% of the 19F signal of the applied NEs 
was still present in the liver, whereas only 20% of signal from the NPs 
remained. Faster clearance of NP compared to NE was confirmed with ex 
vivo MRI and with whole animal in vivo NMR, to verify clearance of the 
19F signal not simply a relocation of the 19F signal within the animal 
(Figs. S3 and S4). We also calculated the biological half-life of the 19F 
signal for NEs and NPs, which revealed that the 19F signal decay from the 
liver is best described by a 2-step exponential decay function (NP R2 
0.84 and NE R2  0.69). The 19F signal decay consisted of a rapid early 
phase (NP t1/2  10 h and NE t1/2  42 h) and a slower late phase (NP 
t1/2  16 days and NE t1/2  100 days). The confidence interval for the 
slow NE t1/2 is very wide (43 – infinite days) and the fit is mediocre, 
which is in part due to the relatively short follow-up period of 28 days, 
and should therefore be interpreted cautiously. Interestingly, we 
observed that the 19F signal in the spleen decreased for both imaging 
agents. 
To investigate whether NPs also show faster local clearance from 
inflammatory lesions, we utilized a model of myocardial infarction. As 
previously described, 19F MRI can be used to image inflammation by in 
situ labeling monocytes and visualizing their recruitment to an inflam-
matory focus [12]. Fig. 1f shows that intravenous injection of NPs 24 h 
after induction of myocardial infarct revealed a strong 19F signal in the 
area of the infarct (Fig. 1f, first panel) indicated by late Gd enhancement 
(LGE; Fig. 1f, fifth panel). However, over the time course of 6 days we 
observed a clear decrease in fluorine signal from the infarcted area 
(Fig. 1f, panel 2–4), which shows that the 19F signal is not only released 
from spleen and liver but also clears from inflammatory lesions. 
3.3. Ultrastructure determines the biological half-life of PFCE-NPs 
To investigate the difference between NPs and NEs that may be 
causative for this considerably shortened biological half-life, we 
formulated two additional PFC-bearing imaging agents (Fig. 2). First, we 
investigated the effect of the surface composition and ultrastructure of 
the nanocarrier. For this purpose, we generated PLGA nanocapsules 
(NCs) with a single PFCE core (single-core PLGA-NCs; Fig. 2c) to 
investigate the clearance of NCs from liver and spleen. NCs were intra-
venously injected in mice, and the animals were imaged repeatedly over 
a period of 14 days. Fig. 2a and b shows that the 19F signal of the NCs is 
not reduced but remains stable in the liver over two weeks. These results 
demonstrate that NCs and NEs show a similar clearance profile which is 
different from the NPs and indicates that the ultrastructure of nano-
particles and not the NP’s surface composition is mainly responsible for 
the enhanced clearance rate of PFCE. 
Second, we investigated the effect of nanocarrier size by formulating 
90 nm sized NEs, similar to those used in previous studies with a very 
long half-life (Fig. 2f) [12,28,51–55]. Again, mice were injected with 90 
nm NEs and clearance was tracked over a five-week period. Interest-
ingly, these smaller NEs show the same long biological half-life as the 
bigger NEs (Fig. 2d and e), indicating that indicating that NEs with a size 
of 180 nm or 90 nm do not significantly differ in their clearance rate 
from the liver. However, the smaller 90 nm NEs showed substantially 
lower splenic and bone marrow uptake, which shows that size does in-
fluence the biodistribution of nanoformulations (Fig. S5). 
3.4. Multicore NPs dissociate into smaller domains 
Since we found that size, biodistribution and surface composition 
does not determine the biological half-life, we wondered what mecha-
nisms would cause such rapid systemic clearance of the injected NP. The 
remaining key difference between the NEs and NPs is the ultrastructure 
since NPs have a multicore structure whereas NEs display only a single- 
core [47]. In contrast to PFC containing NEs, NPs consist of many do-
mains of 24 nm PFCE droplets, each of which is stabilized by a shell of 
PLGA polymer, forming a single 200 nm particle [47]. 
To investigate whether structure influences nanoparticle degrada-
tion, we dissolved multicore NPs and core-shell NCs in physiologically 
buffered saline. At various time points samples were analyzed by AFM 
and DLS (Fig. 3a,c). Both PLGA based NPs and NCs show an initial slight 
increase in diameter which is due to diffusion of water into the particle 
that leads to swelling of the particle [56]. Interestingly, only in the 
multicore NPs, is this followed by disassembly into smaller domains with 
a hydrodynamic diameter of ~50 nm (Fig. 3a,c,d). These results were 
confirmed by AFM (Fig. 3c) which revealed large particles (185 nm 
90 nm) on day one and multiple smaller domains with a mean size of 30 
nm  14 nm after two weeks. Of note, size measured by DLS is an 
overestimation of the PFCE droplet size as a result of the hydrodynamic 
diameter being larger than the actual diameter and the remaining 
polymer coating. In this assay, degradation of NPs and NCs occurred 
through spontaneous hydrolysis and therefore took two weeks to com-
plete. However, many in vivo occurring enzymes speed-up this process to 
occur within 24 h [39,57]. To test whether these domains contain PFCE, 
we performed 19F MRI. PLGA domains suspended in buffer were sub-
jected to 19F MRI which revealed a homogeneous 19F signal throughout 
the solution (Fig. 3b, left). When NPs were completely hydrolyzed by 
NaOH, the 19F signal was shifted to the wall of the plastic tube (Fig. 3b, 
right). Hydrolysis of the NPs in sodium hydroxide releases the PFCE 
content which is not soluble in aqueous buffer and due to its 
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Fig. 1. Only Nanoparticles (NP) are significantly cleared over the five-week follow-up period. A total of 32 mice were injected with 20 mg of PFCE containing 
NPs or a fluorine-equivalent amount of NEs and repetitively scanned over a period of five weeks. a Illustration of the imaging agent’s structure and surface 
composition, NP left, NE right. b Typical size (diameter) distribution as measured with dynamic light scattering. c Representative atomic force microscopy images 
showing size distribution of NP (left) and NE (right). Scan area 1.5 μm  1.5 μm d Representative transversal 1H (greyscale) and 19F (red hot) MRI images 3 h after 
injection to show localization of the fluorine signal in the liver, and a series of 1H/19F MRI images of the liver over time. The rows show NP (top) and NE (bottom) 
liver signal of one individual animal. e Liver (left) and spleen (right) 19F MRI signal over time of mice injected with NPs or NEs. Signal is normalized as a percentage 
of the maximum signal for each individual animal over the follow-up period. Only the NPs show a significant decrease in PFCE signal over time. The dotted lines are 
the two-phase exponential decay fit function of the NP (green) and NE (blue) signal over time. f Merged mid-ventricle short axis view 1H/19F MRI images from a 
mouse injected with NPs 3 h after ischemia-reperfusion myocardial infarction of the left anterior descending coronary artery (LAD). The NPs locate to the infarcted 
region, visible with late gadolinium enhancement images and traced with the dashed line. Over the follow-up period of six days, decrease of the 19F signal within the 
infarct area can be observed. Liver and bone marrow signals were masked to help image interpretation. *  p < 0.0001, error bars represent standard deviation. (For 
interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.) 
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hydrophobicity sticks to the interior of the plastic tube. 
Collectively, we show that multicore NPs can dissociate into smaller 
domains which encapsulate PFCE, which is in contrast to the single-core 
PFCE-nanoparticles NEs or NCs (Fig. 3d). 
3.5. NPs and NCs show a stronger cellular uptake than NEs 
To gain additional insight in the mechanism of the clearance we 
determined the cellular uptake of NPs, NCs and NEs in vitro. We hy-
pothesized that NPs, NCs and NEs are taken up by cells of the reticulo-
endothelial system and then are differentially degraded by these cells. 
Therefore, we investigated the cellular uptake of fluorescently labelled 
NPs, NCs and NEs by cell lines, and cells isolated from liver and spleen. 
Using flow cytometry, we found that NPs, NCs and NEs and showed a 
rapid and strong cellular uptake (Figs. 4a and S6), particularly in cells 
isolated from liver (monocytes, neutrophils, Kupffer cells, hepatocytes). 
Of note, PLGA-based NPs and NCs showed a stronger fluorescence signal 
compared to lipid-based NEs (Fig. 4a). Similar results were observed for 
immune cells (monocytes, neutrophils, B- and T-cells) isolated from 
spleen. However, here splenic neutrophils display a lower level of up-
take of NCs compared to NPs or to hepatic neutrophils. Next, we 
investigated by confocal microscopy if NPs and NEs are internalized into 
the endosomal system of the cells. To this end, we incubated CHO cells 
with fluorescently labelled NPs and NEs and after fixation, the cell 
surface was labelled by wheat germ agglutinin (WGA) and the nuclei 
were counterstained by DAPI. As shown in Fig. 4c, NPs and NE can be 
identified as small vesicular structures in the vicinity of the nucleus. To 
investigate if the particles are taken up by active endocytosis, we 
incubated cells with NPs, NC, and NEs at 37 C and at 4 C which blocks 
endocytic processes and analyzed the time-course of the labelling of the 
cells by flow cytometry. Interestingly, we found that cells incubated 
with NPs/NCs showed a rapid cellular uptake at 37 C (Fig. 4b) which is 
strongly reduced at 4 C. However, cells treated with NEs at 37 C or 4 C 
show a lower amount of cellular labelling which is only weakly 
ameliorated at 4 C. Taken together, this indicates that the strong uptake 
of the PLGA based nanoparticles is due to strong active endocytosis, 
which is not triggered by NEs. 
Taken together, these data show that all the three nanocarriers are 
taken up by cells adept at degradation. Therefore, changes in cellular 
uptake do not explain the different systemic clearance kinetics observed 
between core-shell systems and multicore NPs. 
3.6. PFCE encapsulated in NPs is not released via hepatic or renal routes 
Finally, we explored whether the PFCE might be excreted via hepatic 
or renal route as an additional explanation of the increased clearance of 
the PFCE from the body. PFCs in general are exhaled from the lungs [20, 
58,59]. However, due to their small size and mobility the 30 nm PLGA 
domains might be excreted via the renal or hepatic routes. To investigate 
this, we performed MRI scans of the gallbladder, bladder and intestines 
at the timepoints at which excretion rate was highest (Figs. S7b and d). 
Since we expected to catch up only low amounts of PFCE, we increased 
the voxels size by 10-fold to enable detection of weak signals. However, 
no 19F signal could be registered in these organs (Figs. S7b and d). 
Moreover, we collected all the feces which was produced within in the 
first 24 h after application of NPs, homogenized it with PBS to ensure 
Fig. 2. Nanocarriers with a PLGA surface but a core-shell structure (nanocapsules; NC) or lipid based nanoemulsions (NE) with a smaller diameter do not 
show a decrease in the 19F signal over time. NP clearance rate is most rapid in the first 2 weeks, longitudinal follow-up of NCs and small nanoemulsions (sNE) was 
chosen accordingly. a Representative transversal 1H/19F MRI images of the liver over time of animals injected with NCs. 19F MRI images are in a red hot and overlaid 
onto grey scale 1H MRI anatomical reference images. b19F MRI organ signal over time of mice injected with NCs. Signal is normalized as a percentage of the 
maximum signal for each individual animal over the follow-up period. Liver signal is stable over the entire follow-up duration. c Illustration depicting the NC with a 
PLGA-based core-shell structure. d Representative transversal 1H/19F MRI images of the liver over time of animals injected with sNE. 19F MRI images are in a red hot 
and overlaid onto grey scale 1H MRI anatomical reference images. e19F MRI organ signal over time of mice injected with sNE. Signal is normalized as a percentage of 
the maximum signal for each individual animal over the follow-up period. The spleen signal is decreasing over time. For sNEs, the liver signal remained rather stable 
between day 1 and day 27, except for a sharp decrease on day 21, which was probably due to artefacts such as suboptimal coil tuning, shimming, reference power 
correction to fluorine or positioning of the animal within the coil. f Illustration depicting the sNE. Error bars represent standard error of the mean. (For interpretation 
of the references to colour in this figure legend, the reader is referred to the Web version of this article.) 
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solubilization of the NPs and investigated PFCE signal by high resolution 
NMR-spectroscopy. However, again no traces of PFCE were found in the 
feces (Figs. S7a and c). An alternative possibility is that PFCE in the feces 
might not be stabilized by PLGA and might have condensed into pure 
PFCE droplets. Since PFCE has alike imaging characteristics (i.e. reso-
nance frequency, T1 and T2) as PFCE in NPs, the PFCE in this state would 
be equally visible with MRI (Table S2). Therefore, we conclude that 
PFCE is not massively released via feces either as NP or pure PFCE 
droplet. 
3.7. PFCE containing nanoparticles are biocompatible and non-toxic even 
at very high doses 
Another aspect that is relevant to the clearance of PFC materials from 
the body is acute cellular toxicity, which can lead to cell death with 
subsequent release of NPs, followed by elimination from the body. To 
investigate whether clearance of the NPs might be due to increased 
cellular toxicity we tested cell viability by flow cytometry and also the 
acute and long term effects of intravenous applications of high doses of 
NPs/NEs to mice. 
First, we isolated mouse blood, spleen and liver cells and subjected 
these to NEs and NPs. Cell viability over time was assessed by cytometry 
by DAPI staining. As shown in Fig. 5a, we did not find an increase in the 
amount of DAPI cells over time period of 80 min of incubation and we 
also found no changes in the relative abundances of individual cell types 
(Fig. S8). Then, we treated mice intravenously with double or triple the 
dose of the nanoparticles compared to the previous experiments. During 
the 2-week follow-up, no adverse symptoms were observed and there 
was no difference in bodyweight between the groups. Histology shows 
no morphological changes typical for acute toxicity (Fig. 5b and c). The 
spleen volume did show an increase compared to the control mice, in 
accordance with previously reported findings for NEs [28,60,61]. In 
conclusion, there was no indication for short term toxicity in the mice 
injected with these very high NP doses. Most notably, there was no 
evidence of microvascular obstruction, organ toxicity or animal 
discomfort. 
This is in accordance with previous data of these NPs, both with 
direct injection and after intracellular labelling in primary murine 
pancreatic islets, cardiac stem cells and primary human dendritic cell 
subsets [21,41,46,62,63]. 
4. Discussion 
We have shown that the ultrastructure of multi-core NPs results in a 
unique degradation profile that results in a 15-fold faster clearance 
compared to conventional lipid-based and even PLGA-based single-core 
agents. Furthermore, cellular uptake, toxicity, biodistribution, and 
clearance routes are similar in all three agents. 
Biological clearance is a crucially important property of an imaging 
agent [64,65]. Slow or non-clearance disallows the study of temporal 
changes (e.g. resolving inflammation or death of labelled cells) and 
re-use of an agent in the same animal. Furthermore, regulatory approval 
is difficult despite short-term non-toxicity [19,34,66], particularly given 
the recent issues with Gd retention [32]. In particular, single resonance 
PFCs such as PFCE are known to have prohibitively long in vivo retention 
times [19]. Our results with single-core nanoformulations align with 
Fig. 3. Degradation of the multicore nanoparticles (NP) compared to core-shell nanocapsules (NC). a Size distribution in dynamic light scattering over a 2- 
week period, left NCs, right NPs. Both NPs and NCs show initial swelling, however only NPs show disassembly into domains after two weeks. In contrast, NCs do not 
degrade into smaller domains and only show minor aggregation. b19F MRI of NPs dissolved in phosphate buffered saline for two weeks resulting in disassembly into 
domains (left) and fully degraded NPs (right). Nanodomains (left) still encapsulate all PFCE as depicted by the homogeneous signal distribution in the phantom. After 
complete polymer degradation (right), a phase separation of the PFCE and the aqueous solution occurs which leads to a sticking of the PFCE to the plastic walls of the 
phantom. c Atomic force microscopy images showing freshly dissolved NPs (left) and the same sample after 2 weeks (right), clearly showing disassembly into 
nanodomains. Scan area 1 μm  1 μm d Illustration representing the different degradation patterns of NPs (top) and NCs (bottom). Note the initial swelling of NPs 
followed by breakdown into nanodomains. NCs also show slight swelling but do not degrade into smaller domains. 
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previous studies. Jacoby et al. most notably conducted a study which 
had a follow-up duration of 80 days, this resulted in an estimated sys-
temic PFCE half-life in excess of 250 days [19]. The biological half-life of 
PFCE injected as a multi-core NP is therefore extremely short at less than 
1/15th of that of a single-core lipid-based NE. Thus, multi-core NPs 
allow the use of the PFCs best-suited for imaging, while overcoming 
their slow clearance. 
Long local retention also hampers the clinical utility of 19F MRI. 
When a locally accumulated tracer is not cleared, it cannot reflect res-
olution of inflammation or therapeutic cell viability, in inflammation 
imaging or cell tracking respectively. In vivo cell tracking using 1H/19F 
MRI holds great promise [4,11,67] as it tracks labelled cells with high 
specificity and excellent soft tissue resolution to show their accumula-
tion. Moreover, imaging can also provide information regarding cell 
viability when the imaging agent is cleared from the region of interest 
when cells die. PFCE NEs have been shown to be retained at the site of 
cell transfer long after these cells have died therefore these labels are 
unable to indicate cell viability [28,66]. Here we investigate local 
retention in a murine model of myocardial infarction as a possible 
clinically applicable diagnostic application. Previously, fluorine con-
taining imaging agents with a similar size have been used to in situ label 
immune cells [10,21,41,68]. Here we showed that monocytes and 
neutrophils readily take up nanoparticles in vitro as published previously 
[21]. When multi-core nanoparticles were injected intravenously, they 
show uptake in immune cell reservoirs like the bone marrow, spleen and 
liver. When an inflammatory lesion is present, these labelled cells are 
expected to migrate to the site of inflammation. Indeed, when we 
induced inflammation via a myocardial infarction model, we found 
strong NP accumulation in the injured region. Excitingly, we subse-
quently observed fast decrease of the 19F signal from the infarcted re-
gion, which shows that the 19F signal is not only cleared from the liver 
and spleen, but also from inflamed regions. This could allow for true 
kinetic imaging of cells in vivo, maintaining sensitivity to loss of cells 
from the region of interest. This is in keeping with our previous data 
showing that multi-core NP 19F signal was lost together with a luciferase 
reporter in transplanted pancreatic islets in vivo as the cells died [62]. 
PFCs have several unique properties, like their chemical and bio-
logical inertness which explains why PFCs such as PFCE are not 
metabolized in vivo. Endogenous pH, reactive oxygen species and en-
zymes do not alter or degrade the PFCE molecule. This means we can 
accurately track PFCE biological half-life with MRI and NMR, since PFCE 
is not chemically modified in a way that would change the MR resonance 
frequency in vivo. Another one of these unique features is the immisci-
bility of PFCs in water or fat, which is reflected in their slow clearance 
via the uncommon route of exhalation, and long local retention. 
Consequently, PFC excretion is governed by its rate of re-circulation and 
exhalation, this behavior is dependent on physicochemical properties 
specific for each PFC. Properties such as low vapor pressure and high 
boiling point, molecular weight and lipophobicity explain the slow 
clearance of PFCE. Interestingly, – to the best of our knowledge – the 
impact of nanoparticle structure on the biological half-life has not been 
studied before. Here we show for the first time how changing the ul-
trastructure of a nanoformulation can have relevant impact on PFCE 
clearing rate. We have recently described how the addition of an 
immiscible fluorous phase to a conventional PLGA-nanoparticle pro-
duction method resulted in nano-sized particle with a unique multi-core 
structure [47]. 
Here we use DLS and AFM to show that the ultrastructure of the 
multi-core nanoparticle results in a unique two-step degradation 
pattern. First, the multi-core NP disassembles into 30 nm domains, each 
stabilized by their own polymer shell which keeps them dispersed in 
aqueous media. Based on these findings we suggest that the multi-core 
NP degrades into smaller PFCE-containing domains, with a larger sur-
face area to volume ratio possibly improving re-circulation and evapo-
ration, leading to this much faster clearance (Fig. 6). Other ways of 
impacting 19F biological half-life is using small hydrophilic fluorinated 
molecules. Originally, these probes suffered from low sensitivity and 
toxicity but recently, tremendous progress has been made which led to 
Fig. 4. In vitro uptake studies of PLGA-based -NP and -NC and lipid-based NE. a Flow cytometric analysis of monocytes, neutrophils, Kupffer cells and hepa-
tocytes incubated with fluorescently labelled NP (blue), NC (orange) and NE (green) over a period of 180 min. Percentage of positive cells are shown as mean  SD 
for n  3 individual experiments. b Flow cytometry analysis of RAW 264.7 cells incubated with NP, NC and NE over a period of 180 min at 37 C and 4 C. Percentage 
of positive cells are shown as mean  SD for n  5 individual experiments. c Confocal microscopy images of CHO cells incubated with NPs and NEs for 90 min. The 
cell membrane was stained with WGA488 and the nuclei counterstained with DAPI. Arrows indicate internalized NPs and NEs labelled with Alexa647 and Cy5, 
respectively. The images show a merging of Alexa647/Cy5 (purple), WGA488 (green) and DAPI (blue) measurements. 400 magnification. (For interpretation of the 
references to colour in this figure legend, the reader is referred to the Web version of this article.) 
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the development of small hydrophilic 19F tracers which enabled in vivo 
imaging [69,70]. The here investigated NPs and NEs of 100–200 nm size 
carry a high payload of 19F atoms and are avidly taken up by phagocytic 
cells to enable cell tracking studies. In contrast, small hydrophilic mol-
ecules might display lower uptake by phagocytic cells but might possess 
better tissue penetration-properties and are therefore suited for labelling 
of non-cellular structures like alterations in the extracellular matrix. 
Therefore, different types of fluorinated imaging probes have their 
specific advantages and drawbacks and should be selected accordingly 
for a particular application. 
Here we solve the issues of long systemic half-life and poor local 
mobility, and we show how this aids translation of these NPs to the clinic 
in a myocardial infarct model. Additionally, these nanoparticles can be 
produced GMP-grade and are used to track therapeutic dendric cells in a 
clinical trial (NCT02574377) [42,44,45]. The current study demon-
strates the effect of the nanoparticle ultrastructure on the systemic 
clearance of the PFC-cargo. Formulation of a multi-core structured 
nanoparticle can be achieved by the addition of an inert and non-toxic 
fluorous phase to PLGA-nanoparticles, and could therefore be translat-
able to PLGA-nanoparticles with a drug as cargo. This finding could, 
thereby, introduce a new tool for control over drug delivery [44]. 
5. Conclusions 
19F MRI is an excellent, clinically-translatable candidate for quanti-
tative inflammation imaging or cell tracking, but has been hampered by 
a lack of suitable agents. In particular, the extremely long clearance time 
of PFCE has been a major hurdle. We have presented a PLGA-based 
single resonance 19F-imaging agent, which is biocompatible and local-
izes to immune cell reservoirs of the spleen and bone marrow. Most 
importantly, the particles show a 15-fold faster clearance rate compared 
to core shell NEs, resulting in a biological half-life of 16 days, a time 
frame which is clinically relevant. We show how the unique multi-core 
ultrastructure with unique degradation profile and rapid cell uptake of 
these NPs causes enhanced excretion. The customizability of the multi- 
core PLGA formulation could also allow application to various other 
areas, including drug delivery and blood substitutes (the original clinical 
application of PFCs). 
Overall, the favorable 19F MRI characteristics and short biological 
half-life should help further implementation of PFCs in the clinic. This 
work shows for the first time how the ultrastructure of a PFC-containing 
nanoparticle can dramatically affect biological clearance. 
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